secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001683168-25-003715
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharma Q1 net loss $1.8M; PH-762 shows 4 complete responses in Phase 1b trial
--------------------------------------------------------------------------------

- Cash $13.3M at March 31 vs $5.4M Dec 31; raised $9.2M from offerings and $2.9M from warrant exercises.
- Net loss $1.8M for Q1 2025 vs $2.2M in Q1 2024; R&D expenses down 23% to $0.886M.
- Phase 1b PH-762: 4 of 9 cSCC patients had pathologic complete response; no dose-limiting toxicities.
- 4th cohort enrolling; company expects to complete enrollment in Q3 2025.
- Sufficient capital to complete treatment phase of Phase 1b trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825003715/0001683168-25-003715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316825003715/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-003715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer